JP2016507575A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507575A5
JP2016507575A5 JP2015557226A JP2015557226A JP2016507575A5 JP 2016507575 A5 JP2016507575 A5 JP 2016507575A5 JP 2015557226 A JP2015557226 A JP 2015557226A JP 2015557226 A JP2015557226 A JP 2015557226A JP 2016507575 A5 JP2016507575 A5 JP 2016507575A5
Authority
JP
Japan
Prior art keywords
compound
compound according
formula
group
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507575A (ja
JP6471100B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016100 external-priority patent/WO2014127042A1/en
Publication of JP2016507575A publication Critical patent/JP2016507575A/ja
Publication of JP2016507575A5 publication Critical patent/JP2016507575A5/ja
Application granted granted Critical
Publication of JP6471100B2 publication Critical patent/JP6471100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557226A 2013-02-12 2014-02-12 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン Active JP6471100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763830P 2013-02-12 2013-02-12
US61/763,830 2013-02-12
PCT/US2014/016100 WO2014127042A1 (en) 2013-02-12 2014-02-12 Hydantoins that modulate bace-mediated app processing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019005905A Division JP6773820B2 (ja) 2013-02-12 2019-01-17 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Publications (3)

Publication Number Publication Date
JP2016507575A JP2016507575A (ja) 2016-03-10
JP2016507575A5 true JP2016507575A5 (OSRAM) 2017-02-23
JP6471100B2 JP6471100B2 (ja) 2019-02-13

Family

ID=51354522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557226A Active JP6471100B2 (ja) 2013-02-12 2014-02-12 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
JP2019005905A Active JP6773820B2 (ja) 2013-02-12 2019-01-17 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019005905A Active JP6773820B2 (ja) 2013-02-12 2019-01-17 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Country Status (11)

Country Link
US (6) US20140371283A1 (OSRAM)
EP (2) EP3653609B1 (OSRAM)
JP (2) JP6471100B2 (OSRAM)
KR (2) KR102220259B1 (OSRAM)
CN (1) CN104995176B (OSRAM)
AU (1) AU2014216390B2 (OSRAM)
CA (1) CA2899938C (OSRAM)
DK (1) DK2956443T3 (OSRAM)
ES (2) ES2769578T3 (OSRAM)
IL (1) IL240555B (OSRAM)
WO (1) WO2014127042A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
KR20180090778A (ko) 2015-08-27 2018-08-13 난트뉴로, 엘엘씨 App-선택적 bace 억제를 위한 조성물 및 그의 용도
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
NZ751777A (en) * 2016-08-19 2020-08-28 Foresee Pharmaceuticals Co Ltd Pharmaceutical composition and methods of uses
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107468690B (zh) 2017-08-11 2020-01-31 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
CN107353239B (zh) 2017-08-11 2019-06-18 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法
EP3759079A4 (en) * 2018-03-01 2021-11-17 The Regents Of The University Of California AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE
CN110652516A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN113412089A (zh) * 2018-12-04 2021-09-17 脑部保护私人有限公司 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法
CN113727658A (zh) 2018-12-04 2021-11-30 脑部保护私人有限公司 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法
US11926599B1 (en) 2023-10-23 2024-03-12 King Faisal University 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4995971A (OSRAM) 1973-01-27 1974-09-11
DE2448869A1 (de) 1973-10-19 1975-09-04 Mcneilab Inc 4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel
US4025517A (en) 1975-06-23 1977-05-24 Mcneil Laboratories, Incorporated 4-Oxo-2-hexahydropyrimidinylidene ureas
JPS554305A (en) * 1978-06-13 1980-01-12 Nippon Zoki Pharmaceut Co Ltd Remedy for disease caused by stress and its preparation
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US5070100A (en) 1983-09-14 1991-12-03 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
CH677886A5 (OSRAM) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5387742A (en) 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
DK0568575T4 (da) 1991-01-21 2010-12-20 Elan Pharm Inc Test og model for Alzheimers sygdom
DK0620849T3 (da) 1992-01-07 2003-10-20 Elan Pharm Inc Transgene dyremodeller for Alzheimer's sygdom
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
DE69426571T2 (de) 1993-10-27 2001-08-09 Elan Pharm Inc TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
EP0871720A2 (en) 1995-06-07 1998-10-21 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
CA2343004A1 (en) 1998-09-24 2000-03-30 Pharmacia & Upjohn Company Alzheimer's disease secretase
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
US7161962B1 (en) 1999-05-27 2007-01-09 Nuera Communications, Inc. Method and apparatus for coding modem signals for transmission over voice networks
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
JP4448134B2 (ja) 2003-08-08 2010-04-07 シェーリング コーポレイション ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤
AR045219A1 (es) 2003-08-08 2005-10-19 Pharmacopeia Inc Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
NZ547462A (en) 2003-12-15 2010-06-25 Schering Corp Heterocyclic aspartyl protease inhibitors
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
EP1743170A2 (en) 2004-04-02 2007-01-17 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
IL162288A0 (en) 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
ES2321853T3 (es) 2004-06-16 2009-06-12 Wyeth Difenilimidazopiridina e -imidazol aminas como inhibidores de b-secretasa".
ES2332659T3 (es) 2004-06-16 2010-02-10 Wyeth Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa.
DE602005025363D1 (de) 2004-07-22 2011-01-27 Schering Corp Substituierte amide als inhibitoren der beta-sekretase
AR050184A1 (es) 2004-07-28 2006-10-04 Schering Corp Inhibidores macrociclicos de beta-secretasa
PE20060692A1 (es) 2004-09-21 2006-07-19 Lilly Co Eli Inhibidores bace
EP1851208A1 (en) 2005-01-13 2007-11-07 Novartis AG Macrocyclic compounds useful as bace inhibitors
GB0500683D0 (en) 2005-01-13 2005-02-23 Novartis Ag Organic compounds
US7759354B2 (en) 2005-06-14 2010-07-20 Schering Corporation Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof
WO2006138230A2 (en) 2005-06-14 2006-12-28 Schering Corporation The preparation and use of protease inhibitors
CA2609582A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ES2436795T3 (es) 2005-06-14 2014-01-07 Merck Sharp & Dohme Corp. Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
DE602006018456D1 (de) 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
CN101193892A (zh) 2005-06-14 2008-06-04 先灵公司 大环杂环天冬氨酰基蛋白酶抑制剂
AU2006266167A1 (en) * 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
WO2007038271A1 (en) 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
US7763606B2 (en) 2005-10-27 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7560451B2 (en) 2005-10-31 2009-07-14 Schering Corporation Aspartyl protease inhibitors
WO2007058601A1 (en) * 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
GB0602951D0 (en) 2006-02-14 2006-03-29 Novartis Ag Organic Compounds
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
GB0611064D0 (en) 2006-06-05 2006-07-12 Novartis Ag Organic compounds
EP2644600B1 (en) 2006-06-12 2017-01-11 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
MX2009000710A (es) 2006-07-20 2009-01-30 Novartis Ag Compuestos macrociclicos utiles como inhibidores de bace.
CN101484431A (zh) 2006-07-20 2009-07-15 诺瓦提斯公司 大环内酰胺
BRPI0719336A2 (pt) 2006-11-23 2014-02-04 Novartis Ag Derivados de 2-hidróxi-1,3-diaminopropano
CA2672293A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
JP2010512390A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション 三環式系を含むアスパルチルプロテアーゼ阻害剤
TW200831091A (en) * 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
EP2134342B1 (en) 2007-03-12 2013-01-30 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam cgrp receptor antagonists
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
US20090041201A1 (en) 2007-08-06 2009-02-12 Carestream Health, Inc. Alignment apparatus for imaging system
EP2190833A1 (en) 2007-08-23 2010-06-02 Novartis Ag Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
US20090062361A1 (en) 2007-08-30 2009-03-05 Allergan, Inc. Therapeutic hydantoins
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
JP2011527311A (ja) 2008-07-10 2011-10-27 ノバルティス アーゲー Ｂａｃｅ阻害薬として有用なアミノベンジル置換環状スルホン誘導体
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
AP2011005707A0 (en) 2008-11-11 2011-06-30 Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
US20120165346A1 (en) 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US8877744B2 (en) 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲
KR20180090778A (ko) * 2015-08-27 2018-08-13 난트뉴로, 엘엘씨 App-선택적 bace 억제를 위한 조성물 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2016507575A5 (OSRAM)
JP2016505637A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2016506962A5 (OSRAM)
JP2016505614A5 (OSRAM)
JP2016515561A5 (OSRAM)
JP2010511721A5 (OSRAM)
JP2017509586A5 (OSRAM)
JP2015512931A5 (OSRAM)
JP2016040288A5 (OSRAM)
JP2019517487A5 (OSRAM)
JP2017504611A5 (OSRAM)
JP2016506960A5 (OSRAM)
JP2015508749A5 (OSRAM)
JP2011519956A5 (ja) キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬
JP2012508252A5 (OSRAM)
JP2013533879A5 (OSRAM)
JP2014525420A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2016516043A5 (OSRAM)
JP2016506961A5 (OSRAM)
JP2020097577A5 (OSRAM)
JP2016531126A5 (OSRAM)
JP2011513410A5 (OSRAM)
JP2016130266A5 (OSRAM)